536742-61-7Relevant articles and documents
PTERIDINONE COMPOUNDS AND USES THEREOF
-
Paragraph 0478; 0805; 0810, (2019/11/11)
The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).
Triazinone compound and T-type calcium channel inhibitor
-
Page/Page column 88, (2016/08/29)
There is provided a novel triazinone compound that has an excellent T-type voltage-dependent calcium channel inhibitory activity and is specifically useful for treatment of pain. A compound of Formula (I), a tautomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof: where each substituent is defined in detail in the description or claims, for example R1 is H or C1-6 alkoxy, etc., each of L1 and L2 is independently a single bond or NR2, etc., L3 is C1-6 alkylene, etc., A is C6-14 aryl or 5 to 10-membered heteroaryl which is optionally substituted, etc., B is C3-11 cycloalkylene, etc., D is C6-14 aryl or 5 to 10-membered heteroaryl which is optionally substituted, etc.
Amination of arenes through electron-deficient reaction cascades of aryl epoxyazides
Lang, Stuart,Kennedy, Alan R.,Murphy, John A.,Payne, Andrew H.
, p. 3655 - 3658 (2007/10/03)
(Matrix presented) Aryl epoxyazides undergo efficient electron-deficient reaction cascades mediated by Lewis acids, leading to regiospecific amination of the aromatic ring.